[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"schizophreniform-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:schizophreniform-disorder":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,84,108,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100507653","improving-cognition-through-telehealth-aerobic-exercise-and-cognitive-training-after-a-first-schizophrenia-episode-100507653",false,"NCT05890183","Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a First Schizophrenia Episode","Inclusion Criteria:\n\n1. a first episode of a psychotic illness that began within the past three years;\n2. a diagnosis by DSM-5 of schizophrenia, schizoaffective disorder, or schizophreniform disorder;\n3. age 18 to 45 years of age;\n4. sufficient acculturation and fluency in the English language to avoid invalidating research measures; and\n5. residence likely to be within commuting distance of the UCLA Aftercare Research Program.\n\nExclusion Criteria:\n\n1. premorbid IQ less than 70;\n2. evidence of a known neurological disorder (e.g., epilepsy) or significant head injury;\n3. evidence of moderate or severe substance use disorder within the six months prior to the first episode or evidence of a substance-induced psychosis.","ALL","18 Years","45 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","The participants in the study will receive psychiatric treatment at the UCLA Aftercare Research Program. All participants in this 12-month RCT will receive cognitive training. Half of the patients will also be randomly assigned to the aerobic exercise and strength training condition, and the other half will be randomly assigned to the Healthy Living Group condition. The primary outcome measures are improvement in cognition and level of engagement in the in-group and at-home exercise sessions. Increases in the level of the patient's serum brain-derived neurotropic factor (specifically Mature BDNF) which causes greater brain neuroplasticity and is indicator of engagement in aerobic exercise, will be measured early in the treatment phase in order to confirm engagement of this target. In order to demonstrate the feasibility and portability of this intervention outside of academic research programs, the interventions will be provided via videoconferencing. The proposed study will incorporate additional methods to maximize participation in the exercise condition, including the use of the Moderated Online Social Therapy (MOST) platform to enhance motivation for treatment based on Self-Determination Theory principles, and a \"bridging\" group to help the participants generalize gains to everyday functioning. In addition, the exercise group participants will receive personally tailored text reminders to exercise.",[26,27,28],"Schizophrenia","Schizophreniform Disorder","Schizoaffective Disorder",[30,31,32,33,34,35,36],"First-Episode Schizophrenia","Cognitive Remediation","Physical Exercise","Brain Derived Neurotrophic Factor","Telehealth Intervention","Moderated Online Social Therapy (MOST)","Motivational Text Messaging Program (Chorus)","RECRUITING","2026-08-01",{"date":40,"type":41},"2026-08-04","ACTUAL",{"date":43,"type":41},"2023-05-23",{"date":45,"type":20},"2028-05-31",{"name":47,"class":48},"University of California, Los Angeles","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":62,"conditions":63,"keywords":71,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":49},"100613164","phase-3-cognitive-strategies-in-early-psychosis-2-100613164","NCT07263022","Cognitive Strategies in Early Psychosis 2","COSTEP 2","Inclusion Criteria:\n\n* Between the ages of 18 and 35\n* Onset of a psychosis spectrum illness (schizophrenia, schizoaffective disorder, schizophreniform disorder, psychosis NOS, bipolar disorder with psychosis, or major depressive disorder with psychosis) within 5 years of enrollment\n* Estimated IQ of 70 or above\n* Proficient at English as determined through interactions with the study team\n* No change in psychiatric medication within a week of enrollment or MRI study visits\n* No clinically significant change in any medications for at least 1 month prior to study participation or MRI study visits, as determined by PI\u002FCo-Is\n\n  * Participants may have minor adjustments in medication doses in the past 30 days, per PI discretion, but may not have had major increases or decreases in doses, or additions or removal of medication within the past 30 days.\n  * Participants are to have no changes to medications in the past 7 days before drug administration (i.e., must have been on a stable dose for at least 7 days prior to receiving the study drug).\n\nExclusion Criteria:\n\nMedical Criteria:\n\n* Presence of the following medical concerns as determined by the study PI:\n\n  * Major neurological disorder\n  * History of a clinically significant head injury with or without prolonged unconsciousness\n  * Any major medical condition that, in the opinion of the PI, would impede participation in the study or would put the participant at additional risk by participating\n* History of any of the following as reported by the participant:\n\n  * Renal impairment, injury, or disease\n  * Hepatic impairment, injury, or disease\n  * Myocardial infarction or heart disease, or endorsement of history of or of cardiac symptoms at intake:\n\n    * Dyspnea\n    * Palpitations\n    * Orthopnea\n    * Pedal oedema\n    * Significant dizziness\n    * Syncope\n    * Claudication\n  * Low white blood cell count, or is diagnosed with leukopenia, neutropenia, or agranulocytosis\n* Presence of unmanaged hypertension (\\>140\u002F90) or elevated resting heart rate (\\>100 bpm)\n* Abnormal clinical laboratory values:\n\n  * uACR \\> 30 mg\u002Fg\n  * creatinine level \\>0.95 mg\u002FdL\n  * AST or ALT \\> 50 U\u002FL\n  * Bilirubin \\> 1.2 mg\u002FdL\n  * Total Protein \\\u003C 6 g\u002FdL\n* Taking a medication or supplement that has a major drug interaction with any study drugs (e.g., ketamine, MAOIs, clomipramine, diazepam, propranolol, warfarin)\n* Allergies to study drugs\n* Is pregnant, planning to become pregnant, or is breastfeeding\n* Cannot pass the visual acuity test\n* Cannot pass the CMRR Subject Safety Screen due to MRI contraindications\n\nMental health criteria:\n\n* Meets criteria for a severe substance or alcohol use disorder within 3 months of enrollment\n* Lifetime history of a stimulant use disorder\n* Current manic episode as determined by the MINI\n* History of psychiatric hospitalization within 3 months of enrollment\n* Meets criteria for clinical risk of suicidal behavior, as defined by:\n\n  * Clinician judgment\n  * A suicide attempt within 3 months of enrollment\n  * Active suicidal ideation at screening or baseline, as indicated by the C-SSRS Screener\n  * Previous intent to act on suicidal ideation with a specific plan and\u002For preparatory acts within 3 months of enrollment, as indicated by the C-SSRS Screener\n* Symptom severity scores in the severe (6) or extremely severe (7) range on the BPRS for the following items: suicidality, disorientation, bizarre behavior, excitement, elevated mood\n* Any other psychiatric symptoms or conditions that, in the opinion of the PI, would impede participation in the study or put the participant at additional risk by participating\n\nOther criteria:\n\n* Unable or unwilling to provide informed consent\n* Unable to demonstrate adequate decisional capacity, in the judgment of the consenting study staff member, to make a choice about participating in the research study\n* Current guardianship\n* Is under civil commitment or under a stay of civil commitment\n* Illiteracy\n* Has engaged in significant cognitive training, in the opinion of the PI, in the last year","35 Years",{"count":59,"type":20},24,[61],"PHASE3","The goal of this clinical trial is to learn more about decision making in psychosis spectrum disorders, like schizophrenia. Participants will be people who have had symptoms of a psychosis spectrum disorder start within the last five years. The investigators will study how two study agents change decision making in people with psychosis, by asking participants to complete some brain games on the computer before and after taking the study agents. The investigators hope to improve our understanding of psychosis to help people in the future. The main research questions are:\n\n* Does a single dose of modafinil change how people with psychosis play the brain games?\n* Does a single dose of d-serine change how people with psychosis play the brain games?\n* Does a single dose of modafinil change brain activity?\n* Does a single dose of d-serine change brain activity?\n\nParticipants will:\n\n* Complete an interview and self-report questionnaires.\n* Complete safety screening activities, like a blood draw, a urine drug test, and an alcohol breathalyzer test.\n* Complete functional Magnetic Resonance Imaging (fMRI) scans. fMRI uses magnets to take pictures of the brain. There will be six scanning appointments in the study, with two scans each. Appointments will be about a month apart.\n* Take a single dose of a study agent during each scanning appointment. The study agent will be taken after the first fMRI. There are three study agents in total: modafinil, d-serine, and a placebo. Each participant will take each study agent twice during the study.\n* Play brain games on a computer that measure decision making, thinking, and problem solving skills",[64,65,28,66,67,68,27,69,70],"Psychosis","Schizophrenia Disorder","Major Depressive Disorder With Psychotic Features","Bipolar Disorder With Psychotic Features","Psychosis NOS","Psychotic Disorder","Cognition",[70,72,73,74],"Decision Making","fMRI","Psychosis spectrum disorders","2026-07-22",{"date":77,"type":41},"2026-07-23",{"date":79,"type":41},"2026-07-17",{"date":81,"type":20},"2030-04-30",{"name":83,"class":48},"University of Minnesota",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":21,"phases":92,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100647793","phase-1-longitudinal-pet-imaging-of-antipsychotic-binding-to-the-dopamine-3-receptor-in-schizophrenia-100647793","NCT07715253","Longitudinal PET Imaging of Antipsychotic Binding to the Dopamine-3 Receptor in Schizophrenia","Inclusion Criteria:\n\n1. Individuals, any gender or sex, aged 18 to 55, inclusive at screen\n2. Capable of understanding the study procedures and able to provide informed consent\n3. Diagnosed with schizophrenia, schizoaffective, or schizophreniform disorder\n4. Negative urine toxicology\n5. Antipsychotic free (by choice and for reasons unrelated to the study), and for at least 3 weeks (4 for aripiprazole or LAIs) at the time of the baseline PET scan, inclusive of any antipsychotic-free time prior to consent. \\[Any patient who requires inpatient hospitalization or acute medication treatment for clinical stabilization during the medication free period will not be included in this study; any participant who in the clinical judgment of the PIs or any involved clinician is not stable or appropriate for a medication free period will not be included.\\]\n6. PANSS total score \\> 80 and \\\u003C 120 (inclusive)\n\nExclusion Criteria:\n\n1. Diagnosis of substance use disorder within the previous month\n2. A history of poor or inadequate response or hypersensitivity to CAR or BREX for any reason\n3. EKG abnormality that is clinically significant including a QTc interval \\> 450 msec for men and \\> 470 msec for women,\n4. Pregnant or breast-feeding women. Women of child-bearing potential must have a negative serum β-hCG pregnancy test at Visit 1, must have been using an acceptable method of contraception for 30 days before the study (i.e., before the first PET or MRI scan, whichever comes first), and must agree to do so for the whole study and 30 days after (unless post-menopausal or surgically sterile)\n5. Any clinically significant or unstable medical\u002Fneurological illness, condition, or disorder that is anticipated to potentially compromise participant safety on study medication\n6. Any material in the body that is a contraindication for MRI procedures or participated in prior nuclear medicine procedures in the past year that exceed FDA-defined limits when combined with radiation dosimetry from PET scanning in this protocol to avoid exceeding annual dosimetry limits (metal screener repeated before MRI scan). Individuals exposed to radiation in the workplace in the previous year will be excluded.\n7. Acute risk for suicide (i.e., score of 4-5 within the previous month or 6 within the previous 3 months on the CSSRS) or violence\u002Fhomicide (e.g., homicidal ideation), or history of severe violent behavior or behavioral dyscontrol while antipsychotic-free\n8. A history of treatment resistance to antipsychotics or who have a duration of illness of greater than 20 years\n9. Claustrophobia\n10. Use of nicotine products within the previous month (prior to first PET scan)","55 Years",{"count":19,"type":20},[93],"PHASE1","This is a clinical trial in which 40 participants with schizophrenia will be randomized to 15 days of treatment with cariprazine (CAR) or brexpiprazole (BREX) in a single-blind manner. \\[11C\\]PHNO PET scans will be obtained before treatment and after 1 day and 15 days of treatment to examine the effects of antipsychotic medications on the dopamine-3 receptor (D3R). The overall objectives of the current study are to: 1) measure the acute binding of CAR\u002FBREX to the D3R; 2) measure D3R availability for evidence of upregulation following subchronic administration of CAR\u002FBREX in the same set of patients; 3) examine relationships between subchronic binding of CAR\u002FBREX to, and upregulation of, the D3R vs. D2R and changes in positive symptoms, negative symptoms, and cognitive deficits. Relationships between subchronic binding of CAR\u002FBREX and EPS will be explored.",[28,27,26],[97],"schizophrenia","NOT_YET_RECRUITING","2026-07-15",{"date":101,"type":41},"2026-07-20",{"date":103,"type":20},"2026-12-01",{"date":105,"type":20},"2030-11-30",{"name":107,"class":48},"New York State Psychiatric Institute",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":15,"minAge":116,"maxAge":57,"enrollmentInfo":117,"targetDuration":4,"studyType":21,"phases":119,"briefSummary":120,"conditions":121,"keywords":126,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100642980","feel-good-a-multicenter-trial-of-a-mindfulness-based-group-therapy-in-young-adults-with-early-psychosis-100642980","NCT07645443","FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis","Mindfulness-based Group Therapy in Young Inpatients With Acute Early Psychosis (FEEL-GOOD)","FEEL-GOOD","Inclusion Criteria:\n\n* Age 16 to 35 years\n* Clinical diagnosis of early psychosis, defined as first psychotic episode within the last 5 years as assessed with the Structural Clinical Interview for DSM-5 Research Version (SCID-5-RV)\n* DSM-5 schizophrenia spectrum or other psychotic disorder confirmed with SCID-5-RV (DSM-5: 297.1, 298.8, 295.4, 295.9, 295.7, 298.8, 298.9) Currently receiving inpatient\u002Fday clinic treatment with a planned stay of at least 4 weeks\n* Interested in and willing to participate in FEEL-GOOD and\u002For TAU.\n\nExclusion Criteria:\n\n* Insufficient German language abilities\n* Acute suicidality or acute threat to others","16 Years",{"count":118,"type":20},252,[23],"FEEL-GOOD is a prospective multi-site single-blinded randomized controlled trial in young inpatients with acute early psychosis. Participants are randomized 1:1 to FEEL-GOOD plus treatment as usual (TAU) or TAU alone. The intervention consists of one individual preparatory session and eight modularized group sessions delivered over four weeks involving four to eight participants at each session and including practice and homework tasks. Outcomes are assessed at baseline, 4 weeks post-intervention, and 6 months follow-up, with the primary outcome being observer-rated total psychopathology as measured with the assessed by the total score of the Positive and Negative Syndrome Scale (PANSS) post-treatment (4 weeks post baseline).",[122,123,27,124,125],"Delusional Disorder","Brief Psychotic Disorder","Schizophrenia \u002F Schizoaffective Disorder","Other Psychotic Disorder Not Due to A Substance or Known Physiological Condition",[127,128,129,130,131,132,133,64,134,135,26,136,137],"Randomized controlled trial","Emotion regulation","Ecological momentary assessment","Early psychosis","First-episode psychosis","EMA","Schizophrenia spectrum disorder","Mindfulness","Mindfulness-based Interventions","Schizoaffective disorder","Delusional disorder","2026-07-14",{"date":99,"type":41},{"date":141,"type":41},"2026-05-27",{"date":143,"type":20},"2028-12-31",{"name":145,"class":48},"Stephanie Mehl",8,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":155,"sex":15,"minAge":156,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":21,"phases":160,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":49},"100645599","micrornas-as-biomarkers-in-first-episode-schizophrenia-100645599","NCT07703670","MicroRNAs as Biomarkers in First Episode Schizophrenia","MicroRNAs in Neural-Derived Extracellular Vesicles as Biomarkers in First Episode Schizophrenia","MIRFEST","Inclusion Criteria:\n\n1. Acute first episode of psychosis with DSM-5 diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, or psychosis Not Otherwise Specified (NOS)\n2. Current positive symptoms rated ≥4 (moderate) on one or more of these BPRS items: hallucinatory behavior, unusual thought content, grandiosity, conceptual disorganization\n3. Early phase of illness as defined by having taken antipsychotic drugs for a cumulative lifetime period ≤2 weeks\n4. Age 15 to 40\n5. Receiving or about to start naturalistic treatment with either aripiprazole or risperidone\n6. Full capacity to consent\n\nExclusion Criteria:\n\n* Participant voluntarily withdraws consent at any given time during the study\n* Loss of capacity to consent during the study\n* Treating psychiatrist determines that the participant requires an antipsychotic medication other than aripiprazole or risperidone due to adverse effects, poor tolerability, poor response, or any other reason\n* The investigator, sponsor, independent safety monitor, or DSMB determines discontinuation is necessary to protect the participant\n* Pregnancy is discovered during the study",true,"15 Years","40 Years",{"count":159,"type":20},160,[23],"This study investigates whether tiny molecules called microRNAs (miRNAs), found in special brain-derived \"packages\" (neural-derived extracellular vesicles, or NDEs) that travel from the brain into the blood, can serve as helpful indicators (biomarkers) for schizophrenia. Currently, doctors diagnose schizophrenia and monitor treatment primarily through clinical interviews, which can be slow and imprecise. This study will work with 80 individuals recently diagnosed with first-episode schizophrenia who are beginning treatment with either aripiprazole or risperidone, along with 80 healthy volunteers. Blood samples will be collected from all participants. For individuals with schizophrenia, blood will be drawn at the beginning of treatment and again after 12 weeks. By comparing patterns of brain-derived miRNAs in the blood of patients versus healthy volunteers, and by observing changes in these miRNAs during treatment, the researchers hope to discover whether these molecules can help diagnose schizophrenia more quickly and predict how well a treatment will work. If successful, this study will provide initial evidence that these miRNAs could become valuable new tools leading to earlier, more accurate diagnoses and more personalized treatment selection.",[65,27,28,163],"Psychosis Not Otherwise Specified (NOS)",[165,166,167,168,169],"miRNA","biomarkers","first episode","neural derived extracellular vesicles","exosomes","2026-07-10",{"date":138,"type":41},{"date":173,"type":20},"2026-07-01",{"date":175,"type":20},"2031-05-01",{"name":177,"class":48},"Northwell Health"]